Innoviva, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting a net loss of $73,888 thousand for the third quarter driven primarily by negative changes in fair values of equity and equity method investments.

Key Highlights

  • Q3 2026 Net Loss: Innoviva reported a net loss of $73,888 thousand, or $(1.03) per basic and diluted share, for the three months ended September 30, 2026.
  • Nine-Month Net Income: For the nine months ended September 30, 2026, the company reported net income of $29,287 thousand, or $0.40 per basic and diluted share.
  • Total Revenue: Total revenue for Q3 2026 was $106,120 thousand, compared with $107,800 thousand in Q3 2025; nine-month revenue rose to $323,705 thousand from $296,715 thousand in the prior-year period.
  • Equity Investment Fair Value Declines: Changes in fair values of equity method investments, net, were negative $97,585 thousand in Q3 2026, compared with a positive $30,751 thousand in Q3 2025.
  • Cash and Cash Equivalents: Cash and cash equivalents stood at $581,394 thousand as of September 30, 2026, up from $550,941 thousand at December 31, 2025.
  • Share Repurchases: The company repurchased common stock totaling approximately $78,159 thousand (including accrued excise tax) across the nine months ended September 30, 2026, reducing shares outstanding from 74,636 thousand to 71,536 thousand.
  • Total Stockholders' Equity: Total stockholders' equity was $1,137,518 thousand as of September 30, 2026, compared with $1,172,841 thousand at December 31, 2025.

Innoviva's Q3 2026 Results: Investment Fair Value Swings Drive Quarterly Loss

According to the filing, Innoviva (NASDAQ:INVA) recorded total revenue of $106,120 thousand for the three months ended September 30, 2026, a slight decrease from $107,800 thousand in the same period of 2025. Royalty revenue, net of amortization of capitalized fees paid, was $54,657 thousand in Q3 2026 versus $59,896 thousand in Q3 2025, while net product sales rose to $49,444 thousand from $47,294 thousand. The company reported gross profit of $84,382 thousand for the quarter, up from $75,539 thousand a year earlier.

The filing shows that income from operations for Q3 2026 was $42,153 thousand, compared with $34,578 thousand in Q3 2025. However, the company disclosed that changes in fair values of equity method investments, net, were negative $97,585 thousand in Q3 2026, reversing from a positive $30,751 thousand in Q3 2025. Changes in fair values of equity and long-term investments, net, were also negative $41,904 thousand in Q3 2026 versus a positive $31,510 thousand in the prior-year quarter. These combined swings pushed the company to a loss before income taxes of $97,610 thousand for Q3 2026, against income before income taxes of $97,817 thousand in Q3 2025.

For the nine-month period, the company reported income from operations of $131,162 thousand and net income of $29,287 thousand, compared with net income of $107,012 thousand in the first nine months of 2025. Selling, general and administrative expenses for the nine months ended September 30, 2026 were $104,024 thousand, up from $81,194 thousand in the same period of 2025. Total assets as of September 30, 2026 were $1,537,926 thousand, compared with $1,635,165 thousand at December 31, 2025. As of October 31, 2026, 71,081,477 shares of common stock were outstanding, according to the filing.

What Was Disclosed

Innoviva filed its quarterly report covering the period ended September 30, 2026, disclosing a Q3 net loss of $73,888 thousand driven by negative fair value changes in equity investments, partially offset by operating income of $42,153 thousand. Nine-month net income was $29,287 thousand on total revenue of $323,705 thousand.